HC Wainwright Reaffirms Buy Rating for Krystal Biotech
| KRYS Stock | USD 156.50 0.16 0.10% |
Slightly above 67% of Krystal Biotech's investor base is looking to short. The analysis of the overall investor sentiment regarding Krystal Biotech suggests that many traders are alarmed. Krystal Biotech's investing sentiment can be driven by a variety of factors including economic data, Krystal Biotech's earnings reports, geopolitical events, and overall market trends.
Krystal |
Krystal Biotech s stock had its buy rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a 221.00 target price on the stock. HC Wainwrights target price points to a potential upside of 30.74 percent from the companys
Read at thelincolnianonline.com
 |
Krystal Biotech Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Krystal Biotech can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Krystal Biotech Maximum Pain Price Across January 17th 2025 Option Contracts
Krystal Biotech's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Krystal Biotech close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Krystal Biotech's options.
Krystal Biotech Fundamental Analysis
We analyze Krystal Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Krystal Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Krystal Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Revenue
Revenue Comparative Analysis
Krystal Biotech is currently under evaluation in revenue category among its peers. Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Krystal Biotech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Krystal Biotech stock to make a market-neutral strategy. Peer analysis of Krystal Biotech could also be used in its relative valuation, which is a method of valuing Krystal Biotech by comparing valuation metrics with similar companies.
Peers
Krystal Biotech Related Equities
| APLS | Apellis Pharmaceuticals | 3.92 | ||||
| RGNX | Regenxbio | 0.39 | ||||
| RYTM | Rhythm Pharmaceuticals | 0.1 | ||||
| MGTX | MeiraGTx Holdings | 0.16 |
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.